Lisbon, Portugal (ots/PRNewswire) - Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® ...
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...
Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...
Montreal (ots/PRNewswire) - First commercial launch in Europe Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited. Theratechnologies filed its health ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model Merck, a leading science and technology company, ...
Brussels, Belgium (ots/PRNewswire) - - Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis - Advantage Hers will equip and empower women around the world living with chronic inflammatory diseases, ...
Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...
Toronto (ots/PRNewswire) - Drawing only on trusted medical sources and overlaid with the latest federal health guidelines, COVID AIKnowledgeEnableTM arms healthcare professionals and health conscious individuals with the information they need to make better decisions Real Time Medical ("RTM" or "the Company"), a ...
Munich (ots/PRNewswire) - - Newly presented data provide reassurance around edoxaban use in vulnerable populations of frail, elderly and renally impaired patients - Clinician's perception of frailty found to potentially be a better marker of clinical outcomes than age - The global ETNA-AF programme, which includes ...
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
Munich (ots/PRNewswire) - - Publication highlights Europe-specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients[1] - Findings are ...
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - New research has been launched to better control COVID-19. 18.6 million francs have been invested in projects that will investigate innovative solutions and develop public health recommendations. Mandated by the Federal Council, the SNSF launched the National Research Programme "COVID-19" (NRP 78) on 30 April 2020 to advance our understanding of the ...
Euro Airport Basel-Mulhouse-Freiburg
COVID-19 screening for passengers from countries at risk From Saturday 1 August 2020, in accordance with French legislation, mandatory COVID-19 tests will be carried out at EuroAirport for all travelers from countries at risk. At present, this applies to arrivals from ...
Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...
Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...
Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...
Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...
Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
London and Cambridge, England (ots/PRNewswire) - - Long-term partnership to facilitate cancer research through development of custom antibodies - Agreement to enable global access to resulting reagents and potential diagnostics Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents ...
Hattersheim, Germany (ots/PRNewswire) - European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® ...
Baar, Switzerland (ots/PRNewswire) - The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception. A special call and a ...
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...